MedTrace Logo

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

NCT00234195 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2007-04-17

No results posted yet for this study

Summary

* To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer.
* To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these patients

Conditions

Interventions

DRUG

bupropion extended release (Wellbutrin XL)

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Rajnish Mago, MD · Thomas Jefferson University Department of Psychiatry and Human Behavior

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00234195 on ClinicalTrials.gov